Largest pharmaceutical companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Pfizer leads the 44 pharmaceutical companies in the United States ranked by net assets, at HUF 29.4T, ahead of Johnson & Johnson (HUF 27.72T) and Merck & Co (HUF 17.88T). Figures as of 20 Nov 2026, 13:40 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- PfizerHUF 29.4T
- Median
- HUF 222.1B
- Combined market value
- HUF 1269.94T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | PfizerPFE · Health Care | HUF 29.4T | HUF 53.36T | HUF 9,361.62 | 1.85% down | 10% up | ||
| 2 | Johnson & JohnsonJNJ · Health Care | HUF 27.72T | HUF 218.6T | HUF 90,808.37 | 2.04% down | 31% up | ||
| 3 | Merck & CoMRK · Health Care | HUF 17.88T | HUF 111.3T | HUF 45,145.84 | 3.61% down | 36% up | ||
| 4 | Abbott LaboratoriesABT · Health Care | HUF 17.72T | HUF 61.15T | HUF 35,308.32 | 0.58% down | 19% down | ||
| 5 | Regeneron PharmaceuticalsREGN · Health Care | HUF 10.63T | HUF 32.47T | HUF 313,869.12 | 2.35% down | 22% up | ||
| 6 | Eli LillyLLY · Health Care | HUF 9.02T | HUF 409.1T | HUF 459,283.52 | 2.29% down | 28% up | ||
| 7 | Vertex PharmaceuticalsVRTX · Health Care | HUF 6.35T | HUF 44.87T | HUF 176,986.91 | 2.94% down | 22% up | ||
| 8 | Bristol-Myers SquibbBMY · Health Care | HUF 6.28T | HUF 40.54T | HUF 19,831.40 | 2.05% down | 26% up | ||
| 9 | ViatrisVTRS · Health Care | HUF 5T | HUF 7.75T | HUF 6,757.77 | 1.97% down | 90% up | ||
| 10 | Royalty PharmaRPRX · Health Care | HUF 3.3T | HUF 13.24T | HUF 23,019.92 | 1.38% down | 74% up | ||
| 11 | United TherapeuticsUTHR · Health Care | HUF 2.41T | HUF 8.09T | HUF 190,053.74 | 3.16% down | 18% up | ||
| 12 | Elanco Animal HealthELAN · Health Care | HUF 2.23T | HUF 4.47T | HUF 8,936.71 | 1.54% down | 18% up | ||
| 13 | BioMarin PharmaceuticalBMRN · Health Care | HUF 2.07T | HUF 4.04T | HUF 20,878.38 | 0.02% down | 12% up | ||
| 14 | ZoetisZTS · Health Care | HUF 1.13T | HUF 11.16T | HUF 27,462.78 | 5.59% down | 34% down | ||
| 15 | Ligand PharmaceuticalsLGND · Health Care | HUF 345.8B | HUF 1.95T | HUF 97,538.94 | 3.94% down | 44% up | ||
| 16 | Legend BiotechLEGN · Health Care | HUF 340.6B | HUF 1.06T | HUF 5,472.84 | 0.92% down | 43% down | ||
| 17 | Praxis Precision MedicinesPRAX · Health Care | HUF 298.5B | HUF 2.95T | HUF 105,683.62 | 1.87% up | 83% up | ||
| 18 | Alnylam PharmaceuticalsALNY · Health Care | HUF 268.3B | HUF 6.73T | HUF 50,248.16 | 1.06% down | 66% down | ||
| 19 | Belite BioBLTE · Health Care | HUF 261.9B | HUF 2.08T | HUF 51,335.93 | 3.33% down | 25% up | ||
| 20 | InsmedINSM · Health Care | HUF 251.2B | HUF 10.77T | HUF 49,106.00 | 20.58% up | 27% down | ||
| 21 | Spyre TherapeuticsSYRE · Health Care | HUF 243.1B | HUF 3.15T | HUF 33,187.17 | 3.77% down | 302% up | ||
| 22 | Summit TherapeuticsSMMT · Health Care | HUF 224B | HUF 2.87T | HUF 3,593.04 | 0.67% up | 35% down | ||
| 23 | TG TherapeuticsTGTX · Health Care | HUF 220.3B | HUF 3.33T | HUF 22,054.53 | 1.88% down | 103% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | HUF 220.2B | HUF 2.42T | HUF 22,088.52 | 4.15% down | 16% down | ||
| 25 | Cogent BiosciencesCOGT · Health Care | HUF 216.3B | HUF 1.64T | HUF 9,429.60 | 0.25% down | 25% down | ||
| 26 | Protagonist TherapeuticsPTGX · Health Care | HUF 209B | HUF 2.75T | HUF 42,157.87 | 2.47% down | 45% up | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | HUF 204.9B | HUF 3.13T | HUF 134,863.03 | 0.34% down | 28% down | ||
| 28 | Edgewise TherapeuticsEWTX · Health Care | HUF 177.5B | HUF 1.53T | HUF 13,994.84 | 0.48% down | 82% up | ||
| 29 | Dianthus TherapeuticsDNTH · Health Care | HUF 167.7B | HUF 1.62T | HUF 28,836.09 | 1.01% up | 105% up | ||
| 30 | Ionis PharmaceuticalsIONS · Health Care | HUF 166.3B | HUF 1.54T | HUF 9,252.84 | 0.62% down | 64% down | ||
| 31 | Oruka TherapeuticsORKA · Health Care | HUF 160.4B | HUF 2.25T | HUF 33,166.77 | 1.91% up | 233% up | ||
| 32 | Arrowhead PharmaceuticalsARWR · Health Care | HUF 158.4B | HUF 2.1T | HUF 14,837.86 | 1.25% up | 8% up | ||
| 33 | Definium TherapeuticsDFTX · Health Care | HUF 113B | HUF 1.37T | HUF 10,021.08 | 1.24% up | 176% up | ||
| 34 | ErascaERAS · Health Care | HUF 110.5B | HUF 1.7T | HUF 4,833.78 | 3.34% up | 387% up | ||
| 35 | Mirum PharmaceuticalsMIRM · Health Care | HUF 107B | HUF 2.12T | HUF 32,466.52 | 3.27% up | 35% up | ||
| 36 | Rhythm PharmaceuticalsRYTM · Health Care | HUF 47.3B | HUF 2.75T | HUF 39,703.59 | 1.88% down | 15% up | ||
| 37 | Travere TherapeuticsTVTX · Health Care | HUF 39B | HUF 1.58T | HUF 16,418.52 | 3.86% down | 39% up | ||
| 38 | Axsome TherapeuticsAXSM · Health Care | HUF 30B | HUF 2.43T | HUF 46,121.43 | 1.25% up | 9% down | ||
| 39 | Amneal PharmaceuticalsAMRX · Health Care | -HUF 24.1B | HUF 2.53T | HUF 7,271.06 | 2.24% down | 79% up | ||
| 40 | VeradermicsMANE · Health Care | -HUF 41.1B | HUF 1.78T | HUF 42,283.64 | 0.38% down | 230% up | ||
| 41 | PTC TherapeuticsPTCT · Health Care | -HUF 69.8B | HUF 1.66T | HUF 19,826.30 | 3.16% down | 26% down | ||
| 42 | CytokineticsCYTK · Health Care | -HUF 224.2B | HUF 2.44T | HUF 17,492.69 | 0.27% up | 21% down | ||
| 43 | BridgeBio PharmaBBIO · Health Care | -HUF 709.3B | HUF 5.18T | HUF 26,575.57 | 0.22% up | 15% up | ||
| 44 | AbbVieABBV · Health Care | -HUF 1.11T | HUF 170.37T | HUF 96,383.19 | 0.86% down | 20% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 339.9 HUF).
Questions and answers
Which pharmaceutical companies in the United States rank first by net assets?
Pfizer (HUF 29.4T), Johnson & Johnson (HUF 27.72T) and Merck & Co (HUF 17.88T) are the top three of the 44 pharmaceutical companies in the United States ranked by net assets as of 20 Nov 2026, 13:40 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by net assets.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by net assets have a combined market value of HUF 1269.94T as of 20 Nov 2026, 13:40 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by net assets”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.